Unraveling the pathophysiologic role of galectin‐3 in chronically injured liver
Journal of Cellular Physiology · 2023-04 · 238 (4) · 673-686
DOI: 10.1002/jcp.30956 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cellular Physiology, online erschienen am 06.02.2023. Verfasst von Devaraj Ezhilarasan. Beteiligte Einrichtung: Department of Pharmacology, Molecular Medicine and Toxicology Lab, Saveetha Dental College, Saveetha Institute of Medical and Technical Sciences, Che…. Hauptthemen laut MEDLINE: Galectin 3, Liver. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 139 Literaturangaben.
Abstract (Originalsprache)
Galectin‐3 (Gal‐3) previously referred to as S‐type lectins, is a soluble protein that specifically binds to β‐galactoside carbohydrates with high specificity. Gal‐3 plays a pivotal role in a variety of pathophysiological processes such as cell proliferation, inflammation, differentiation, angiogenesis, transformation and apoptosis, pre‐mRNA splicing, metabolic syndromes, fibrosis, and host defense. The role of Gal‐3 has also been implicated in liver diseases. Gal‐3 is activated upon a hepatotoxic insult to the liver and its level has been shown to be upregulated in fatty liver diseases, inflammation, nonalcoholic steatohepatitis, fibrosis, cholangitis, cirrhosis, and hepatocellular carcinoma (HCC). Gal‐3 directly interacts with the NOD‐like receptor family, pyrin domain containing 3, and activates the inflammasome in macrophages of the liver. In the chronically injured liver, Gal‐3 secreted by injured hepatocytes and immune cells, activates hepatic stellate cells (HSCs) in a paracrine fashion to acquire a myofibroblast like collagen‐producing phenotype. Activated HSCs in the fibrotic liver secrete Gal‐3 which acts via autocrine signaling to exacerbate extracellular matrix synthesis and fibrogenesis. In the stromal microenvironment, Gal‐3 activates cancer cell proliferation, migration, invasiveness, and metastasis. Clinically, increased serum levels and Gal‐3 expression were observed in the liver tissue of nonalcoholic steatohepatitis, fibrotic/cirrhotic, and HCC patients. The pathological role of Gal‐3 has been experimentally and clinically reported in the progression of chronic liver disease. Therefore, this review discusses the pathological role of Gal‐3 in the progression of chronic liver diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Molecular Medicine and Toxicology Lab, Saveetha Dental College, Saveetha Institute of Medical and Technical Sciences, Chennai, Tamil Nadu, India.
Zitieren
APA
Ezhilarasan, D. (2023). Unraveling the pathophysiologic role of galectin‐3 in chronically injured liver. Journal of Cellular Physiology, 238(4), 673-686. https://doi.org/10.1002/jcp.30956
Vancouver
Ezhilarasan D. Unraveling the pathophysiologic role of galectin‐3 in chronically injured liver. Journal of Cellular Physiology. 2023;238(4):673-686. doi:10.1002/jcp.30956
BibTeX
@article{Ezhilarasan2023,
author = {Ezhilarasan, Devaraj},
title = {Unraveling the pathophysiologic role of galectin‐3 in chronically injured liver},
journal = {Journal of Cellular Physiology},
year = {2023},
volume = {238},
number = {4},
pages = {673--686},
doi = {10.1002/jcp.30956}
}
EUVIMED